Metoclopramide intranasal - Evoke Pharma

Drug Profile

Metoclopramide intranasal - Evoke Pharma

Alternative Names: Emitasol; EVK 001; Gimoti™; Pramidin

Latest Information Update: 17 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Questcor Pharmaceuticals
  • Developer Evoke Pharma; Questcor Pharmaceuticals
  • Class Aminobenzoic acids; Antiemetics; Antineoplastics; Benzamides; Chlorobenzenes; Diethylamines; Gastrokinetics; Phenyl ethers; Radiation-sensitising agents; Radiosensitisers; Small molecules
  • Mechanism of Action Dopamine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting
  • Preregistration Diabetic gastroparesis
  • Discontinued Gastroparesis

Most Recent Events

  • 16 Aug 2018 US FDA accepts NDA for metoclopramide intranasal for Diabetic gastroparesis for review
  • 04 Jun 2018 Preregistration for Diabetic gastroparesis in USA (Intranasal)
  • 04 Jun 2018 Evoke Pharma expects to receive notification from FDA regarding NDA filing in August 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top